Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00666822 · ClinicalTrials.gov registry record

Compliance to a Hormone Therapy Regimen in Breast Cancer

A clinical trial of Breast Cancer, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
178
Enrollment target
1
Study location

NCT00666822 is a study of Breast Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 178 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00666822, a study of Breast Cancer, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
178 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Understanding how well patients comply with their treatment regimen may help doctors plan the best treatment and ongoing care. PURPOSE: This clinical trial is studying whether patients comply with their hormone therapy regimen in women with estrogen receptor-positive stage I, stage II, or stage IIIA breast cancer.

Conditions Studied

Interventions

  • OTHER medical chart review
  • OTHER questionnaire administration
  • BEHAVIORAL compliance monitoring

Study Locations (1)

Ohio

  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2007-12
Est. Completion 2015-12

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT00666822

The ClinicalTrials.gov registry entry for NCT00666822 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which medical chart review is the first listed.

NCT00666822 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00666822 about?

NCT00666822 is a clinical study titled "Compliance to a Hormone Therapy Regimen in Breast Cancer". RATIONALE: Understanding how well patients comply with their treatment regimen may help doctors plan the best treatment and ongoing care. PURPOSE: This clinical trial is studying whether patients comply with their hormone therapy regimen in women with estrogen receptor-positive stage I, stage II, o...

What is the current status of trial NCT00666822?

This trial is currently completed. The enrollment target is 178 participants. The study started on 2007-12. Estimated completion is 2015-12.

What conditions does trial NCT00666822 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00666822?

The interventions under investigation include: medical chart review (OTHER), questionnaire administration (OTHER), compliance monitoring (BEHAVIORAL).

Who is sponsoring clinical trial NCT00666822?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00666822 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.